other

Updated:

Blackrock Neurotech

Implantable brain technology changing lives. | Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries.

Blackrock Neurotech logo

Blackrock Neurotech

Implantable brain technology changing lives. | Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries. Our mission is simple: We want people with neurological disorders to walk, talk, see, hear, and feel again. We’re engineering the next generation of neural implants, including implantable brain-computer interface technology that restores function and independence to individuals with neurological disorders.

General information

Firm type

other

Location

Region

North America

Country

United States

City

Salt Lake City

Corporate office

630 Komas Drive, Suite 200, Salt Lake City, UT 84108, United States

Principals

Marcus Gerhardt

Co-Founder & CEO

Florian Solzbacher

Co-Founder & CSO

Christian Angermayer

Co-Chairman

Tim Sievers

Co-Chairman

Thomas Thiele

CFO

Sector focus

NeuroscienceMedTechAI/MLDeep Tech

Frequently asked questions

Who runs investment decisions at Blackrock Neurotech?

Marcus Gerhardt serves as CEO. The board is co-chaired by Christian Angermayer, founder of Apeiron Investment Group, and Tim Sievers, founder of Deposit Solutions. Strategic direction involves both executive leadership and academic co-founder Florian Solzbacher (per the firm's website).

How does Blackrock Neurotech source its technology and IP?

The core technology originates from research at the University of Utah, where co-founder Florian Solzbacher holds a chaired professorship. The firm has licensed or transferred university-developed patents into a commercial platform, typical of university spinouts in the neurotechnology space.

What investment stages does Blackrock Neurotech typically target?

The firm does not invest in external companies — it is an operating company that develops and commercializes its own neurotechnology products. Its stage focus is on clinical and commercial deployment rather than external portfolio building.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Salt Lake City other profiles